ArticleMMWR. Morbidity and mortality weekly report2023
Geographic Distribution of Suspected Alpha-gal Syndrome Cases - United States, January 2017-December 2022.
Article in MMWR. Morbidity and mortality weekly report, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 105 citations in OpenAlex.
- Total Hip Arthroplasty in a Patient With Alpha-Gal Syndrome.Arthroplasty today · 2026Review
- Human monoclonal antibodies targeting α-Gal restrict IgE engagement of α-Gal syndrome allergens.The Journal of clinical investigation · 2026Article
- Perioperative Considerations for Alpha-Gal Syndrome: A Literature Review and Single-Center Experience in a Highly Endemic Area.Diseases (Basel, Switzerland) · 2026Review
- Review
- Article
- Heparin-Induced Anaphylaxis With Cardiac Arrest in a Patient With Alpha-Gal Syndrome: A Case Report.Cureus · 2026Article
- Alpha-gal xenoantigens in bioprosthetic valve recipients: clinical implications for bioprosthesis longevity.Journal of cardiothoracic surgery · 2026Review
- CRISPR-mediated engineering of bovine satellite cells for Alpha-Gal Syndrome-compatible cultivated meat.bioRxiv : the preprint server for biology · 2026Article
- Article
- The Prevalence of Alpha-Gal IgE among Patients with Confirmed Lyme Serology Result.International archives of allergy and immunology · 2026Article
- Alpha-gal Syndrome Symptom Profiles and Diagnostic Experiences Among Farmer and Ranchers.medRxiv : the preprint server for health sciences · 2026Article
- Beefing Up Awareness: Navigating Alpha-Gal Syndrome.Clinical journal of oncology nursing · 2026Review
- Prevalence of Adverse Drug Reactions: Comparing Crotalidae Immune Polyvalent Antivenoms F(ab')Annals of emergency medicine · 2026Article
- Quantification of Alpha-Gal Expression in Commercial BioProsthetic Heart Valves and Its Potential Mitigation.Structural heart : the journal of the Heart Team · 2026Article
- Article
- Alpha-gal sensitization and allergic transfusion reactions: a scoping review protocol.Systematic reviews · 2026Article
- A Human Monoclonal Antibody Targeting α-Gal Ameliorates Experimental Cutaneous Leishmaniasis.The Journal of infectious diseases · 2026Article
- Alpha-gal sensitization and allergic blood transfusion reactions: a scoping review.Journal of translational medicine · 2026Article
- Misdiagnosis of alpha-gal syndrome as non-celiac gluten sensitivity or lactose intolerance: A diagnostic blind spot for clinicians.World journal of gastroenterology · 2026Review
- From vector to allergen: exploring the immunology of tick-triggered α-Gal syndrome.Frontiers in immunology · 2026Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alpha-gal syndrome (AGS) is an emerging, tick bite-associated allergic condition characterized by a potentially life-threatening immunoglobulin E (IgE)-mediated hypersensitivity to galactose-alpha-1,3-galactose (alpha-gal), an oligosaccharide found in most nonprimate mammalian meat and products derived from these mammals. Specific symptoms and severity of AGS vary among persons, and no treatment or cure is currently available. During 2010-2018, more than 34,000 suspected cases of AGS were identified in the United States, but current knowledge of where cases occur is limited. This study examined alpha-gal-specific IgE (sIgE) antibody testing results submitted to the commercial laboratory responsible for nearly all testing in the United States before 2022 to assess the geographic distribution and magnitude of this emerging condition. During January 1, 2017-December 31, 2022, a total of 357,119 tests were submitted from residences in the United States, corresponding to 295,400 persons. Overall, 90,018 (30.5%) persons received a positive test result in the study period, and the number of persons with positive test results increased from 13,371 in 2017 to 18,885 in 2021. Among 233,521 persons for whom geographic data were available, suspected cases predominantly occurred in counties within the southern, midwestern, and mid-Atlantic U.S. Census Bureau regions. These data highlight the evolving emergence of AGS and can be used to help state and local health agencies initiate surveillance and target public health outreach and health care provider education to high-risk localities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.